Chen JM, Zhong YT, Tu C, Lan J. Significance of serum fibroblast growth factor-23 and miR-208b in pathogenesis of atrial fibrillation and their relationship with prognosis. World J Clin Cases 2020; 8(16): 3458-3464 [PMID: 32913852 DOI: 10.12998/wjcc.v8.i16.3458]
Corresponding Author of This Article
Jun Lan, MD, Chief Physician, Department of Cardiovascular Medicine, Dongguan Songshan Lake Central Hospital, Dongguan Institute of Cardiovascular Disease, No. 1 Xianglong Road, Dongguan 523326, Guangdong Province, China. dglanjun@163.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 26, 2020; 8(16): 3458-3464 Published online Aug 26, 2020. doi: 10.12998/wjcc.v8.i16.3458
Table 1 Comparison of general data between the two groups, n (%)
Group
n
Male
Age (yr)
BMI (kg/m2)
Smoking
Drinking
Observation
240
168 (70.00)
60.50 ± 9.28
23.30 ± 5.44
103 (42.92)
63 (26.25)
Control
150
98 (65.33)
59.22 ± 10.11
22.83 ± 6.50
56 (37.33)
34 (22.67)
t/χ2
0.927
1.280
0.769
1.192
0.634
P value
0.336
0.201
0.442
0.275
0.426
Table 2 Comparison of serum fibroblast growth factor-23 and miR-208b levels in the two groups
Group
n
FGF-23 (ng/mL)
Relative expression of miR-208b
Observation
240
210.20 ± 89.60
5.30 ± 1.22
Control
150
110.04 ± 32.29
2.90 ± 0.88
t
13.162
20.926
P value
0.000
0.000
Table 3 Comparison of serum fibroblast growth factor-23 and miR-208b in different subgroups of observation group
Group
n
Man, n (%)
Age (yr)
FGF-23 (ng/mL)
Relative expression of miR-208b
LAD (mm)
LVEDD (mm)
LVESD (mm)
LVEF (%)
Paroxysmal atrial fibrillation
134
98 (73.13)
61.02 ± 10.11
191.20 ± 65.59
4.88 ± 1.02
34.03 ± 4.02
50.03 ± 6.03
32.10 ± 5.58
53.30 ± 7.81
Persistent atrial fibrillation
106
70 (66.04)
59.89 ± 9.92
234.22 ± 70.05
5.83 ± 1.00
38.81 ± 5.11
49.81 ± 5.82
32.01 ± 6.02
52.83 ± 8.10
t
1.419
0.867
-4.896
-7.227
-8.112
0.285
0.120
0.455
P value
0.234
0.387
0.000
0.000
0.000
0.776
0.905
0.649
Table 4 Comparison of serum fibroblast growth factor-23 and miR-208b in patients with and without a major cardiovascular event
Group
n
Man, n (%)
Age (yr)
FGF-23 (ng/mL)
Relative expression of miR-208b
MACE
58
43 (74.14)
61.19 ± 10.54
243.30 ± 72.29
6.12 ± 1.12
Non-MACE
182
125 (68.68)
62.28 ± 9.89
199.65 ± 71.43
5.04 ± 1.07
t
0.624
-0.719
4.041
6.619
P value
0.43
0.473
0.000
0.000
Citation: Chen JM, Zhong YT, Tu C, Lan J. Significance of serum fibroblast growth factor-23 and miR-208b in pathogenesis of atrial fibrillation and their relationship with prognosis. World J Clin Cases 2020; 8(16): 3458-3464